Thanks for reminding us that we need to trust in the science. Very good people are moving this effort forward. With the new CEO perhaps enough interest can be generated to spin a good partnership. A solid partner would go a long way to advance the science and build future funding avenues.
Be careful as you must wait 31 days before reentering unless you want to invoke a wash sale. April could bring some modest movement up so evaluate the risk reward for leaving at this price. Good luck with your decision.
Thank you for your courage. We all hope the best for you as you engage each day in this struggle to extract a full measure of life even as you battle the knowledge of your situation. I hope the FDA will see how valuable the "quality of life" is to those who face these daunting circumstances. AF could care less about your daily battle. Life does have a way of dealing with people like him. Hopefully CUR and/or other worthy investigations will find a treatment that will bring yu a better quality of life.
you got a great deal. The pipeline is intact and the phase III will result in a protocol for selection of patients most likely to benefit from this particular treatment. This will address Adam's complaint. Eva suggested as much not too long ago and I think the presentation today alluded to same. The quick profit traders have abandoned this post and the new buyers can look forward to a steady return to a share price supported by the two recent upgrades. Upgrades are not done without a significant amount of due diligence. Failure to apply industry standards to a recommendation can result in serious litigation. This is why the longs need to hold the line. This panic will pass and Garr may in fact want to do a blog to reaffirm the direction and the positive bias of this data. I certainly hope he does as he is the CEO and what is good for the share price is ultimately good for the continued funding of the science and his position.
Not to worry.... most of the conflict centers on the STEM/CUR litigation. Some people simply must win an argument regardless of the points made. Absent this acrimony I think the message volume would be 40% current level. I also believe the content would be consistent with the excellent posts my many of the board contributors. The knowledge base supporting the analysis of the science is outstanding. I look forward to reading and learning from these posts. After the verdict is in the STEM and CUR supporters will take their separate paths. Good luck to both companies as both simply want to improve the prognosis for their respective patients.